Sun, Dec 22, 2024
[Archive]
Volume 31, Issue 145 (March & April 2023)
J Adv Med Biomed Res 2023, 31(145): 109-116 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sayehmiri K, Norozi S, Tavan H. The Efficacy of Atorvastatin and Rosuvastatin on the Changes of alpha and beta Apolipoproteins; A Systematic Review and Meta-Analysis. J Adv Med Biomed Res 2023; 31 (145) :109-116
URL: http://journal.zums.ac.ir/article-1-6813-en.html
URL: http://journal.zums.ac.ir/article-1-6813-en.html
1- Psychosocial Injuries Research Center, Ilam University of Medical Sciences, Ilam, Iran
2- Dept. of Cardiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran
3- Student Research Committee, Ilam University of Medical Sciences, Ilam, Iran ,hamedtavan@gmail.com
2- Dept. of Cardiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran
3- Student Research Committee, Ilam University of Medical Sciences, Ilam, Iran ,
Abstract: (11121 Views)
Background and Objective: Vascular stenosis is one of the causes of cardiovascular diseases (CVDs). Implementing appropriate therapeutic measures for CVDs requires preventing the progression of stenosis. The purpose of this study was to evaluate the efficacy of atorvastatin and rosuvastatin on the levels of alpha and beta apolipoproteins using systematic review and meta-analysis.
Materials and Methods: This review was performed based on the PRISMA protocol. The ISI, Cochrane Library, Google Scholar, PubMed, and Scopus databases were independently searched by two researchers. MeSH keywords were used to recruit related articles published between 2005 and 2018. Meta-analysis was conducted in STATA 11.1software.
Results: A total of 65 articles were found. Out of these, nine studies were ultimately included in meta-analysis. The findings showed that alpha lipoprotein level increased by 4.24 mg/dl (95% CI: -0.03; -8.45) and 8.71 mg/dl (95% CI: -1.95; -15.48) in patients treated with atorvastatin and rosuvastatin, respectively. Also, patients treated with either atorvastatin or rosuvastatin showed 40.55mg/dl (95% CI: 32.16; 45.93) and 44.78 g/dl (95% CI: 34.16; 55.39) decreases in beta-lipoprotein levels, respectively.
Conclusion: According to the results, rosuvastatin is more effective than atorvastatin in reducing alpha apolipoprotein and increasing beta apolipoprotein levels within a short period of time.
Keywords: Atorvastatin, Rosuvastatin, Alphaapolipoprotein, Beta apolipoprotein, Systematic review, Meta-analysis
Full-Text [PDF 865 kb]
(7865 Downloads)
| | Full-Text (HTML) (732 Views)
✅According to the results, rosuvastatin is more effective than atorvastatin in reducing alpha apolipoprotein and increasing beta apolipoprotein levels within a short period of time.
Type of Study: Review Article |
Subject:
Epidemiologic studies
Received: 2022/03/6 | Accepted: 2022/12/21 | Published: 2023/03/13
Received: 2022/03/6 | Accepted: 2022/12/21 | Published: 2023/03/13
References
1. Nikseresht M, Dabidy-Roshan V. Noninvasive evaluation of myocardial ischemia in patients with heart problems. Tehran Univ Med J. 2018; 75 (12) :869-874
2. Sadeghi M, Pourmoghaddas Z, Yazdekhasti S, Amid S. Association between severity of coronary disease and apolipoproteins A and B. Iran J Endocrinol Metab. 2011; 13 (2) :173-178
3. Schussler O, Lila N, Perneger T,et al . Recipients with blood group A associated with longer survival rates in cardiac valvularbioprostheses.EBioMedicine. 2019 ,3964(19)30126-4.
4. Kim HK, Chang SA, Choi EK, et al. Association between plasma lipids, and apolipoproteins and coronary artery disease : a cross-sectional study in a low-risk Korean population. Int J Cardiol 2005; 101: 435-40. [DOI:10.1016/j.ijcard.2004.03.057] [PMID]
5. Naghavi M, Libby P, Falk F, et al. From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessment strategies: Part II. Circulation 2003; 108: 1772-8. [DOI:10.1161/01.CIR.0000087480.94275.97] [PMID]
6. Sadeghi M, Roohafza H, Afshar H, et al. Relationship between depression and apolipoproteins A and B: a case-control study. Clinical (Sao Paulo) 2011; 66: 113-7. [DOI:10.1590/S1807-59322011000100020] [PMID] [PMCID]
7. Dana N, Safavi S, Nili N, Seyed Tabatabaei BE, HaghjooyJavanmard S. Histological and biochemical characteristics of arteries and veins in patients candidate for coronary bypass surgery . Tehran Univ Med J. 2014; 72 (6) :379-388
8. Hedayati M, Daneshpour M. Evaluation of HDL-C determination methods. Iran J Endocrinol Metabolism. 2005; 7 (4) :365-373
9. Shojaei S, Daneshpour MA, Halalkhor S, Azizi F, Hedayati M. Genetic association between metabolic syndrome and apolipoproteins. Iran J Endocrinol Metab. 2011; 13 (2) :209-220
10. Zarkesh M, Daneshpour MS, Hedayati M, Azizi F. Association of apolipoprotein A-IV gene G360T polymorphism with metabolic syndrome: Tehran Lipid and Glucose Study. Iran J Endocrinol Metab. 2012; 14 (1) :10-17
11. Mashaykhi NR, Sadrneya S, Chehrei A, Javaheri J, Ahmadlou M. The correlation between serum apo lipoprotein A1 and Apo lipoprotein B with coronary artery disease and its severity. J Arak Uni Med Sci. 2013; 16 (6) :82-89
12. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.Circulation. 2005;112(22):3375-83. [DOI:10.1161/CIRCULATIONAHA.104.532499] [PMID]
13. Sabino AP, De Oliveira Sousa M, Lima LM, et al. ApoB/ApoA-I ratio in young patients with ischemic cerebral stroke or peripheral arterial disease. Translat Res. 2008; 152(3):113-8. [DOI:10.1016/j.trsl.2008.06.005] [PMID]
14. Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E. Prognostic utility of ApoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2009; 29(3):424-30. [DOI:10.1161/ATVBAHA.108.181735] [PMID]
15. Sweetnam P, Bolton C, Downs L, et al. Apolipoproteins A-I, A-II and B, lipoprotein (a) and the risk of ischaemic heart disease: the Caerphilly Study. Europ J Clin Investigat. 2000; 30(11):947-56. [DOI:10.1046/j.1365-2362.2000.00725.x] [PMID]
16. Badfar G, Shohani M, Nasirkandy MP. Epidemiology of hepatitis B in pregnant Iranian women: a systematic review and meta-analysis.ArchVirol. 2018;163(2):319-30. [DOI:10.1007/s00705-017-3551-6] [PMID]
17. Badfar G, Shohani M, Mansouri A, Soleymani A, Azami M. Vitamin D status in Iranian pregnant women and newborns: a systematic review and meta-analysis study.Expert Rev Endocrinol Metab. 2017;12(5):379-89. [DOI:10.1080/17446651.2017.1365596] [PMID]
18. Vasigh A, Abdi A, Borji M, Tarjoman A. The prevalence of neuropathy among type 1 diabetic adolescents in Iran: a systematic review and meta-analysis. Int J Adolesc Med Health. 2019 , 26;33(4). [DOI:10.1515/ijamh-2018-0223] [PMID]
19. Anton FH, Stalenhoef Ch, Cinzia S, et al. A Comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.Eur Heart J. 2005;26(24): 2664-72. [DOI:10.1093/eurheartj/ehi482] [PMID]
20. Keith C, Ferdinand Luther T, Clark E,et al. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol.2006; 38: 229-35 [DOI:10.1016/j.amjcard.2005.08.026] [PMID]
21. Jong-Seon P, Young-Jo K, Ji-Yong Ch ,et al. Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia. Korean J Internal Med. 2010; 25(1):27-35 [DOI:10.3904/kjim.2010.25.1.27] [PMID] [PMCID]
22. Hai-yan Q, Ya-wei X, Gui-hua J, Zhi-yun W, Yun Zh, Mei Zh.Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm Res. 2008:26(4):958-64 [DOI:10.1007/s11095-008-9798-6] [PMID]
23. Abate N, Catapano AL, Ballantyne CM, et al. Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses.J Clin Lipidol. 2008;2(2):91-105. [DOI:10.1016/j.jacl.2008.02.002] [PMID]
24. Furuyama F, Koba S, Yokota Y, Tsunoda F, Shoji M, Kobayashi Y. Effects of cardiac rehabilitation on high-density lipoprotein-mediated cholesterol efflux capacity and paraoxonase-1 activity in patients with acute coronary syndrome .J Atheroscler Thromb. 2018 :1;25(2):153-169. [DOI:10.5551/jat.41095] [PMID] [PMCID]
25. Lablanche JM, Leone A, Merkely B, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study. Arch Cardiovasc Dis. 2010; 103(3):160-9. [DOI:10.1016/j.acvd.2010.01.005] [PMID]
26. Otokozawa S, Ai M, Van Himbergen T, et al .Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels. Atherosclerosis. 2009;205(1):197-201. [DOI:10.1016/j.atherosclerosis.2008.11.001] [PMID] [PMCID]
27. Vavlukis M, Mladenovska K, Daka A, et al. Effects of rosuvastatin versus atorvastatin, alone or in combination, on lipoprotein (a).Ann Pharmacother. 2016; 50(8):609-15. [DOI:10.1177/1060028016652415] [PMID]
28. Anagnostis P, Selalmatzidou D, Polyzos SA, et al. Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study. Int J ClinPract 2011; 65:679-83. [DOI:10.1111/j.1742-1241.2011.02655.x] [PMID]
29. Ferdinand KC, Clark LT, Watson KE, et al. Comparison of ef fi cacy and safety ofrosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol 2006; 97:229-35. [DOI:10.1016/j.amjcard.2005.08.026] [PMID]
30. Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of rosuvastatin and atorvastatin across their dose range in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol 2003;91:33-41. [DOI:10.1016/S0002-9149(02)02994-6] [PMID]
31. Jones PH, Davidson MH, Stein EA, et al.Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol. 2003; 92:152-60 [DOI:10.1016/S0002-9149(03)00530-7] [PMID]
32. Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein(a): a randomized, double-blind, placebo-controlled phase 1 study. Lancet.2015; 386:1472-83. [DOI:10.1016/S0140-6736(15)61252-1] [PMID]
33. Jones P, Davidson M,Evan A, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92:152-60. [DOI:10.1016/S0002-9149(03)00530-7] [PMID]
34. Jones P, Hunninghake D,Ferdinand K, et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia additional results from the STELLAR trial. ClinTher 2004; 26:1388-488. [DOI:10.1016/j.clinthera.2004.09.006] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
